Daniel Hornburg, PhD in

Daniel Hornburg, PhD

Inquirer · DISC type cd
Vice President Biomarkers & Precision Medicine (global) at Bruker
📍 San Francisco, California, United States

Daniel Hornburg is the Vice President of Biomarkers & Precision Medicine at Bruker, leveraging his extensive background in multi-omics and mass spectrometry. An alumnus of the Max Planck Society and Stanford University, he has a proven track record of driving technology advancements in fast-paced startups, including pivotal contributions to Seers successful IPO.

Fueled by a deep curiosity for understanding how things work, Daniel has had a lifelong interest in science and space. He believes science encourages a collaborative, "need-to-learn" perspective and appreciates gaining knowledge from people with different viewpoints and backgrounds. He approaches challenges with optimism and a desire for discovery.

He received the prestigious HUPO 2022 Proteomics Science and Technology Award for his interdisciplinary research that enabled groundbreaking proteomics technology.

Read the full overview →
Experience
14 Years
Current Role
Vice President Biomarkers & Precision Medicine (global)
Job Level
Senior
Location
San Francisco, California, United States
Personality Overview

How Daniel shows up

Judgemental
ROI Conscious
Upfront

They can be nudged to make faster decisions by offering what they value. They respond well to confident salespeople. They care equally about the product and its potential impact.

Priorities

Topics Daniel cares about

Precision Medicine
His current role is focused on translating proteomics and biomarker discoveries into tangible patient impact, such as developing non-invasive cancer tests.
Proteomics Technology
Leads the global strategy for next-generation proteomics tech at Bruker, including innovations in LC-MS, spatial proteomics, and single-cell analysis.
+5 more topics Login to view topics
Career

Work history

11-2023
Vice President Biomarkers & Precision Medicine (global)
Bruker
5-2022 - 11-2023
Vice President Proteomics
Seer
9-2021 - 5-2022
Senior Director Discovery
Seer
9-2020 - 9-2021
Principal Scientist
Seer
8-2019 - 11-2023
Scientific Consultant: Multi-omics bioinformatics
Stanford University School of Medicine
In the press

Media appearances

Bruker Announces Advancements in Immunopeptidomics, de novo PTM Analysis and Proteoform Profiling. Featured in Newswire Today
See now
Education
Postdoctoral Scientist
Stanford University
Dr. rer. nat. (PhD)
Max Planck Society
Social presence
in
Behavioral profile

DISC profile (public)

c

Calculativeness (C)

Calculativeness (C) reflects the degree to which a person is likely to be cautious, systematic and analytical. Those scoring high tend to emphasise quality and accuracy.

Other Bruker Employees

Explore more public profiles from related professionals.

Marco Schuchmann
Marco Schuchmann
Director Treasury
Bruker

More profiles

Discover additional public profiles from our index.

NS
Nina Sanapareddy
Senior Director, Clinical Data Curation
Natera
 Fiona Hyland
Fiona Hyland
Director of R&D, Informatics
Thermo Fisher Scientific
 Dee Shorten
Dee Shorten
Partnerships Specialist: API First, SaaS, Payments, and Fintech
Self-employed
 Jasreet H.
Jasreet H.
Director of Strategic Operations and Portfolio, Therapeutics & Innovations
Natera
Unlock the full playbookSee exactly how to sell to Daniel. Free, 10 seconds.